Welcome to our dedicated page for Liquidia SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Liquidia's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Liquidia's regulatory disclosures and financial reporting.
Liquidia Corp director-affiliated entities reported open-market sales of common stock. Entities linked to Stephen M. Bloch, primarily Canaan VIII L.P. and Canaan Partners VIII LLC, sold a total of 196,111 shares of Liquidia common stock in several open-market transactions on June 12 and June 15, 2026, at weighted average prices around $71–$72 per share. Footnotes state that Bloch disclaims beneficial ownership of securities held by the Canaan entities except for any pecuniary interest and that he did not participate in the investment decision under a communications-screen policy. Following these transactions, indirect holdings reported for the Canaan entities remained above 980,000 shares, while Bloch’s direct holding entry shows 65,712 shares as of June 12.
Liquidia Corp Chief Human Resource Officer Sarah Krepp sold 24,880 shares of common stock in open-market transactions. The trades occurred on June 11, 2026 at a volume-weighted average price of $70.2784 per share. The shares were acquired under Liquidia’s 2020 Employee Stock Purchase Plan and the sales were effected pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026. The filing also notes that Krepp continues to hold unvested restricted stock units from multiple prior grants.
Liquidia Corp director-affiliated fund reports large share sale. An investment entity associated with director Stephen M. Bloch, Canaan VIII L.P., sold 388,223 shares of Liquidia common stock in open-market transactions on June 10–11, 2026.
The sales were executed at weighted average prices with underlying trade prices ranging from $64.00 to $72.48 per share, depending on the specific tranche. The footnotes state that Canaan Partners VIII LLC, as general partner of Canaan VIII L.P., collectively makes the investment and voting decisions and that Bloch disclaims beneficial ownership of these securities except for any pecuniary interest through his limited liability company interests.
The filing also shows a separate direct holding of 65,712 shares of Liquidia common stock for Bloch as of June 10, 2026, distinct from the fund’s indirect holdings.
LQDA Rule 144 notice: The filing lists proposed sales of Common stock tied to employee plans and restricted stock units and discloses three recent dispositions by Sarah Krepp. The filing shows 5,749 shares under an Employee Stock Purchase Plan and 19,131 Restricted Stock Units.
The reported dispositions by Sarah Krepp total individual transactions of 276, 4,557, and 16,261 shares on 06/01/2026, 04/13/2026, and 03/13/2026, with proceeds shown as $16,800.12, $174,852.09, and $617,918.00.
Issuer LQDA filed a Rule 144 notice reporting an intended sale of 200,000 shares of common stock. The filing lists multiple recent sales by Canaan VIII LP in the past three months, with dated entries and per‑trade share counts and dollar amounts, including a 06/10/2026 sale of 94,365 shares for 6,039,000.
Liquidia Corp Chief Development Officer Sanjeev Khindri reported an open-market sale of 4,134 shares of common stock on June 8, 2026 at a price of $65.46 per share. After this transaction, he directly holds 67,132 common shares.
According to the footnotes, the sale was effected under a Rule 10b5-1 trading plan adopted on March 9, 2026 and was made to cover taxes tied to the settlement of previously granted restricted stock units. The filing also notes additional equity incentives, including 27,744 unvested RSUs from a February 10, 2025 grant and 34,274 RSUs granted on January 16, 2026 that had not vested as of this Form 4.
Liquidia Corp director-affiliated entity reports open-market share sales. A fund associated with director Stephen M. Bloch sold a total of 220,835 shares of Liquidia common stock in open-market transactions on June 8 and June 9, at weighted average prices around $64–$66 per share.
The securities are held directly by Canaan VIII L.P., whose investment and voting decisions are made collectively by the managers of Canaan Partners VIII LLC. Bloch disclaims beneficial ownership of these securities except to any pecuniary interest through his interests in Canaan Partners VIII LLC and did not participate in the investment decision due to a communications-screen policy. Separately, the filing shows Bloch directly holding 65,712 Liquidia shares.
Liquidia Corp director Paul B. Manning reported open-market sales of 200,000 shares of common stock on June 4, 2026. The shares were sold indirectly through entities he controls or co-manages at weighted average prices in the low-to-mid $60s per share, with price ranges between about $62.21 and $64.61 as disclosed in multiple footnotes.
After these transactions, the filing shows Manning with ongoing indirect holdings in investment vehicles and joint accounts, as well as direct ownership, including 3,131,794 shares held by the Paul B. Manning Revocable Trust where he has sole voting and investment power.
Liquidia Corporation filed a report to share that it will be added to the S&P SmallCap 600® Index, effective before the market opens on June 22, 2026. The company highlights this as a milestone reflecting its market capitalization, liquidity, publicly traded float and profitability profile.
Liquidia develops therapies for challenging respiratory and vascular diseases using its PRINT® technology, including YUTREPIA® (treprostinil) inhalation powder, the investigational L606 formulation and a marketed generic Treprostinil Injection. The company notes that forward-looking statements about visibility, strategy and long-term value are subject to risks described in its SEC filings.
Liquidia Corp director-related entity sells shares while retaining a large position. An investment entity associated with director Stephen M. Bloch, Canaan VIII L.P., sold a total of 84,800 shares of Liquidia common stock in open-market transactions on June 4–5, 2026 at weighted average prices around $64–$66 per share. The filing states these securities are held by the Canaan entities, that Dr. Bloch disclaims beneficial ownership beyond any pecuniary interest, and that he did not participate in the investment decision due to a communications-screen policy. After these sales, the filing reports 1,785,242 shares held indirectly through Canaan entities and 65,712 shares held directly.